Cargando…

Prostanoid therapies in the management of pulmonary arterial hypertension

Prostacyclin is an endogenous eicosanoid produced by endothelial cells; through actions on vascular smooth-muscle cells, it promotes vasodilation. Pulmonary arterial hypertension (PAH) is characterized by elevated mean pulmonary artery pressure due to a high pulmonary vascular resistance state. A re...

Descripción completa

Detalles Bibliográficos
Autor principal:	LeVarge, Barbara L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386780/ https://www.ncbi.nlm.nih.gov/pubmed/25848300 http://dx.doi.org/10.2147/TCRM.S75122

Ejemplares similares

Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension
por: Al-Qadi, Mazen, et al.
Publicado: (2021)

Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020)

Identification of iron and heme utilization genes in Aeromonas and their role in the colonization of the leech digestive tract
por: Maltz, Michele, et al.
Publicado: (2015)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy
por: Rammo, Richard, et al.
Publicado: (2017)

Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension
por: Speich, Rudolf, et al.
Publicado: (2013)

Altered Prostanoid Metabolism Contributes to Impaired Angiogenesis in Persistent Pulmonary Hypertension of the Newborn
por: Mahajan, Chaitali N., et al.
Publicado: (2014)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Significance of Pulmonary Endothelial Injury and the Role of Cyclooxygenase-2 and Prostanoid Signaling
por: Nickl, Rosa, et al.
Publicado: (2023)

Complex Role for E‐Prostanoid 4 Receptors in Hypertension
por: Herrera, Marcela, et al.
Publicado: (2019)

Prostanoid Metabolites as Biomarkers in Human Disease
por: Idborg, Helena, et al.
Publicado: (2022)

The Link between Prostanoids and Cardiovascular Diseases
por: Beccacece, Livia, et al.
Publicado: (2023)

The limits of oral therapy in pulmonary arterial hypertension management
por: Liu, Qian-Qian, et al.
Publicado: (2015)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

Prostanoid Receptors in the Human Vascular Wall
por: Norel, Xavier
Publicado: (2007)

Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation
por: Alqarni, Abdullah A., et al.
Publicado: (2022)

Effect of Prostanoids on Human Platelet Function: An Overview
por: Braune, Steffen, et al.
Publicado: (2020)

Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension
por: Yamagishi-Kimura, Reiko, et al.
Publicado: (2018)

Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy
por: McCarthy, Elisa K., et al.
Publicado: (2018)

Prostanoid EP(2) Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
por: Patel, Jigisha A., et al.
Publicado: (2018)

Advances in the management of pulmonary arterial hypertension
por: Deshwal, Himanshu, et al.
Publicado: (2021)

Diagnosis and management of pulmonary arterial hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022)

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)

Diagnosis and Management of Pulmonary Arterial Hypertension
por: Houtchens, Jeanne, et al.
Publicado: (2011)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Recent advances in the management of pulmonary arterial hypertension
por: Tsai, Halley, et al.
Publicado: (2016)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective
por: Hansen, Lillian, et al.
Publicado: (2018)

Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
por: Harvey, Lloyd D., et al.
Publicado: (2017)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023)

Increased role of E prostanoid receptor-3 in prostacyclin-evoked contractile activity of spontaneously hypertensive rat mesenteric resistance arteries
por: Liu, Bin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_narufsdrroh3nqtet8eof4dkm3